The presence of ocular surface disease in patients on glaucoma therapy is gaining attention among eye care providers. Recently, three glaucoma specialists and an ocular surface specialist assembled to share their clinical insights and to discuss the medical evidence relevant to the intersection of IOP management and ocular surface health. This CE activity presents highlights of the latest evidence and the faculty’s experiences regarding the prevalence of OSD in patients with glaucoma or ocular hypertension, the effects of preservatives in ocular antihypertensives on the ocular surface, and best IOP-lowering practices to optimize patient outcomes.